Shilpa Medicare is locked its upper circuit limit at Rs. 939.10, up by 44.70 points or 5.00% from its previous closing of Rs. 894.40 on the BSE.

The scrip opened at Rs. 891.00 and has touched a high and low of Rs. 939.10 and Rs. 880.00 respectively. So far 17446 shares were traded on the counter.

The BSE group 'T' stock of face value Rs. 1 has touched a 52 week high of Rs. 1003.20 on 16-Jun-2025 and a 52 week low of Rs. 530.50 on 07-Apr-2025.

Last one week high and low of the scrip stood at Rs. 939.10 and Rs. 846.05 respectively. The current market cap of the company is Rs. 9153.23 crore.

The promoters holding in the company stood at 44.23%, while Institutions and Non-Institutions held 18.52% and 37.25% respectively.

Shilpa Medicare has received EIR with VAI (voluntary action indicated) classification for Unit VI, Dabaspet, Bengaluru, Karnataka, from U.S. Food and Drug Administration (USFDA). The GMP inspection was conducted from October 24-30, 2024. This facility is capable of manufacturing, packaging, testing, storage and distribution of two types of complex dosage forms - Oral Dissolving Films and Transdermal Systems. 

The Unit is already approved by EMA, Europe; MHRA, UK; SFDA, Saudi and TGA, Australia. This Unit is currently supplying Oral Film products to US and other markets. Transdermal products have been filed in the European market.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.